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Figure S1 (sensitive or resistant) cells were cultured in the presence of bevacizumab (1 mg/ml), sunitinib (20 μM) or their respective controls for 10 days and colonies were stained and photographed. C-D. PC3 and C4-2 cells were cultured in the presence of bevacizumab (1 mg/ml), sunitinib (20 μM) or their respective controls for 72 hours and cell viability was analyzed using the MTT assay. E. PC3 and C4-2 cells were cultured in the presence of pazopanib (10 μM) or DMSO for 10 days and colonies were stained and photographed. F. PC3 and C4-2 resistant and sensitive cell lines were cultured in the presence of pazopanib (10 μM) or DMSO for 72 hours and cell viability is analyzed using the MTT assay. No. of colonies hIgG Beva Prostatospheres: Prostatospheres were generated as described (8) . Briefly, cells (5000 cells/well) were cultured in suspension in serum-free DMEM-F12 (Invitrogen), supplemented with B27 (1:50, Life Technology), 20 ng/mL EGF (Peprotech), and 4 µg/mL insulin (Sigma) in 6-well Ultra-low attachment plate (Corning). In some experiments, the drugs were added while plating cells. The prostatospheres were cultured for 6 days and 1 ml culture media was added every other day (along with required drugs). Spheres larger than 100 µm were counted.
GTPase assays: Ras activity was measured using a glutathione S-transferase (GST) fusion protein containing the Ras-binding domain (RBD) of Raf-1 as described (4) . Rac activity assays were performed using the Rac/cdc42 binding domain of PAK (PBD)-GST fusion protein (9).
Anchorage-independent growth assay: Anchorage-independent growth assay was performed by counting the number of colonies formed in medium (DMEM supplemented with 10% FBS) containing 0.3% agarose, with a 0.5% agarose medium underlay as described (10) . Cells were seeded on 60-mm diameter plates in triplicate. Cells were fed with 1.5 mL of suspension medium (DMEM supplemented with 10% FBS) every 3 days and the number of colonies, which were larger than 100 µm in size was counted after 14 days.
IHC and TUNEL staining: Prostate tumors were obtained from the UMASS Cancer Center Tissue Bank with approval of the Institutional Review Board (IRB) of UMASS Medical School. Formain-fixed paraffinembedded sections from primary tumors were stained using either a P-Rex1 or a Myc Ab as described (10) . Tissue microarrays containing 54 primary prostate cancer tissues with matched benign and tumor were kindly provided by Rosina Lis and Massimo Loda (Dana-Farber Cancer Institute, Boston, MA). The DeadEnd Fluorometric TUNEL kit (Promega) was used to stain the xenograft sections according to the manufacturer's instructions.
Plate-based inhibition assay:
The ability of the mcr84 antibody to inhibit the interaction of VEGF-A and Nrp was assessed using a plate-based inhibition assay, using an established procedure (1). AP-VEGF-A was incubated with varying concentrations of antibody, and the mixture was added to Nrp affinity plates, incubated for one hour, washed, and developed using 1X alkaline phosphatase pNPP substrate. C-fur-Sema, a semaphorin-derived competitive inhibitor (11) , was used as a positive control and IgG as negative control. AP activity was measured by measuring absorbance at 405nm using a SpectraMax M5 instrument (Molecular Devices, Sunnyvale, CA).
